Custom Small Activating RNA (saRNA) Synthesis

Small activating RNA (saRNA) is a synthetic RNA molecule that activates endogenous gene expression by targeting specific regions of a gene and inducing transcriptional activation to upregulate gene expression. CD Formulation's research and process development teams optimize unique saRNA sequence designs to customize saRNA products for clients that offer high expression efficiency, prolonged expression duration, ease of detection, and suitability for both in vivo and in vitro research scenarios.

What is small activating RNA (saRNA)?

Small activating RNA (saRNA) can inhibit the proliferation, invasion, and migration of cancer cells by upregulating or activating the expression of target genes through specific sequences in the promoters of oncogenes. As a novel research tool, the mechanism of saRNA action is complex, and as an increasing amount of saRNA research data has been validated, its mechanism of action is gradually being elucidated. The designability, specificity, long-lasting effects, and universality of saRNA in targeting genes have made it more feasible to activate the expression of oncogenes for tumor treatment.

With its unique ability to enhance the transcription of target genes, saRNA activation offers several technical advantages over traditional exogenous gene expression.

• RNA activation of nearly all target genes restores the natural function of these genes.
• Anchoring the target gene's initiation site and the upstream promoter region facilitates sustained activation of target genes.
• No exogenous gene sequences are involved, and the genomic sequence information remains unaltered.

Explore Our Small Activating RNA (saRNA) Synthesis Services

CD Formulation offers custom synthesis of small activating RNA products, along with product design and modification services. This ensures high RNA quality and enhances downstream protein expression, thereby accelerating your innovative projects.

Custom Synthesis Service for saRNA

We co-transcriptionally cap saRNAs to produce saRNAs with a Cap 1 structure, achieving high efficiency. saRNAs with a Cap 1 structure are more compatible with mammalian systems and exhibit greater transcription efficiency compared to those with a Cap 0 structure. The increased transcriptional efficiency, along with the inhibition of RNA-mediated innate immune activation, enhances RNA stability and longevity both in vitro and in vivo. We can customize enhanced green fluorescent protein (EGFP) saRNA, NLuc-EGFP saRNA, firefly luciferase (FLuc) saRNA, and various other reporter gene products.

Modification Services for saRNA

Gene activation can be enhanced by introducing chemical modifications into saRNA molecules, which improves their stability and biological activity. This process ensures safety and efficacy in therapeutic applications while facilitating more efficient regulation of gene expression.

Our Capabilities

Therapeutic IVT RNA Development: IVT Vector Design, Cloning, RNA Production, and Purification

LNP Encapsulation: Standard Formulations and Customized Formulations

General Workflow for Small Activating RNA (saRNA) Preparation

Fig.1 Flow chart of small activating RNA (saRNA) preparation. (CD Formulation)

• Target Gene Selection

Define the target genes that must be activated to ensure that the saRNA is designed effectively to enhance the expression of these genes.

• Small Activating RNA Design

The design of an appropriate saRNA sequence involves selecting the optimal RNA sequence length, GC content, and specificity region to enhance binding efficiency and activation effectiveness.

• Chemical Modification

To improve the stability and intracellular delivery of saRNAs, chemical modifications can be applied.

• Synthesis and Purification

The saRNA is synthesized based on the designed saRNA sequence and subsequently purified to eliminate unreacted precursors and by-products.

• Functional Validation

The synthesized and purified saRNA must undergo functional verification through cellular assays, qPCR, Western blotting, and other analytical techniques.

• Optimization

The optimization of saRNA involves adjusting its design or modifying it to enhance efficiency and stability under specific experimental conditions.

Our Small Activating RNA (saRNA) Synthesis Technology Platforms

CD Formulation fully utilizes our nucleic acid design platform for precise sequence design, our nucleic acid preparation platform for efficient synthesis and purification, and our analytical testing platform for functional validation and quality assessment in the customization of small activated RNAs. We are dedicated to offering personalized and tailored services to ensure that each project meets its specific research objectives.

Our technology platforms include the following:

• Nucleic Acid Drug Design Platform
• Nucleic Acid Drug Preparation Platform
• Analytical Technology Platform

Highlights of Small Activating RNA (saRNA) Synthesis Services

• For sequence optimization technology to improve expression levels.
• A highly specialized team dedicated to designing and optimizing your saRNA for maximum expression, yield, and quality.
• Screened and validated replicase components and modifications.
• Multiple vectors are available to support a variety of applications, each with distinct immunogenicity profiles.

Publication Data

CD Formulation's custom synthesis service for small activated RNA (saRNA) offers an advanced platform for efficient nucleic acid synthesis and modification. By integrating innovative technologies, we provide tailored solutions to meet the specific needs of research and drug development. Contact us to discuss how we can create a customized solution for your project.

How It Works

STEP 1

Submit a service request describing your specific research or development need.

STEP 2

We'll email you to provide your quote and confirm order details if applicable.

STEP 3

Execute the project with real-time communication, and deliver the final report promptly.